Participated · Seed · Jun 2026

Channel Robotics is developing a patented handheld AI-enabled endoscopic robotic platform designed to deliver robotic-level dexterity through existing flexible endoscopes. The company aims to expand access to advanced endoscopic procedures by avoiding large capital-intensive robotic systems and enabling use across hospitals, ambulatory surgery centers, and community practices. Channel plans to continue prototype refinement, expand engineering and product development, and advance manufacturing and quality systems ahead of regulatory submission. Management targets an FDA submission in 2027 and is preparing for commercial launch following regulatory clearance. Financially, Channel has raised a total of $4.6 million across a $2.1 million Seed and a $2.5 million Seed+ led by True Ventures, which will fund the company’s near-term development and regulatory milestones. Founded by Dr. Philip Weissbrod and Dr. Michael Yip, the company emphasizes practical, scalable robotic solutions that integrate into existing clinical workflows.

Participated · Seed · May 2026

Blank Bio develops RNA foundation models that learn from the molecular complexity of tumor transcriptomes to improve patient-level prediction in oncology. The company deploys its models across predictive biomarkers, prognostic biomarkers and patient trajectory modeling, and clinical diagnostics to support patient stratification, biomarker discovery, and improved test sensitivity and specificity. Blank Bio plans to use its recent seed financing to continue model development, expand collaborations with pharma and diagnostic partners, and generate new long-read RNA-seq datasets. As part of a strategic collaboration with PacBio, Blank Bio will produce PacBio HiFi long-read bulk RNA sequencing data from up to 100 fresh-frozen tumor samples, with sequencing performed at Seattle Children’s Research Institute and Kinnex libraries automated on the SPTLabtech firefly+ platform. The team includes AI scientists and engineers from Recursion, Deep Genomics, DeepMind, and Amazon and researchers from institutions including Memorial Sloan Kettering Cancer Center, Stanford, and the Vector Institute, and has published work in Nature Methods, Nature Genetics, Nature Biotechnology, ICML, and NeurIPS. The company is headquartered in San Francisco and intends to apply its models to support pharmaceutical trial design and RNA-seq–based diagnostics.

Led · Series B · May 2026

Founded in 2021 and headquartered in San Diego, 9amHealth provides AI-enabled virtual specialty care for conditions such as obesity, diabetes, hypertension, and dyslipidemia. The company offers an integrated model combining specialized clinicians (including endocrinologists and obesity medicine specialists), at-home lab testing, medication management, and continuous care. 9amHealth partners with employers, health plans, and pharmacy benefit managers and reports more than $50 million in projected medical and pharmacy savings across two Fortune 100 employers. It has delivered pharmacy cost savings amid rising demand for GLP-1 therapies while improving engagement and clinical outcomes. Backed by investors including Define Ventures, SemperVirens VC, 7Wire Ventures, and The Cigna Group Ventures, the company plans to expand its platform to manage a broader set of high-cost, specialty-level chronic conditions.

Participated · Series B · Apr 2026

Luminai builds an AI-native platform that turns unstructured and fragmented healthcare data into trusted intelligence to power end-to-end automation of administrative and operational workflows. The platform combines healthcare-trained AI models, a configurable workflow engine and human-in-the-loop validation, and offers flexible deployment options including on-premises, customer-managed cloud and managed infrastructure. Luminai targets complex operational areas such as access, revenue cycle and compliance where workflows span disconnected systems and unstructured inputs. The company operates with forward-deployed teams that include applied AI talent and healthcare operators drawn from organizations like Palantir, Epic and Banner Health. Luminai says its approach focuses on intelligent orchestration rather than task-specific point solutions. The company has raised $60 million in total capital following the $38 million Series B.

Participated · Seed · Apr 2026

Valius Sciences is a healthcare diagnostics company focused on cancer treatment and diagnostics. The company is based in San Francisco. Financially, it has just completed a Series Seed financing that raised more than $10 million. Sidley served as legal counsel on the financing. The articles do not provide further details on products, operating metrics, or use of funds.